CMPS
COMPASS Pathways plc [CMPS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CMPS Stock Summary
Top 10 Correlated ETFs
CMPS
Top 10 Correlated Stocks
CMPS
In the News
CMPS Financial details
Company Rating
-
Market Cap
568.97M
Income
-118.75M
Revenue
3.68M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
186
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-4.16
Forward P/E
-
PEG
-3.91
P/S
-
P/B
1.92
P/C
-
P/FCF
-5.27
Quick Ratio
17.79
Current Ratio
18.55
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.39
EPS next Y
-
EPS next Q
-
EPS this Y
7.87%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20.9%
-
-
-
-
SMA20
24%
SMA50
-15.84%
SMA100
-16.4%
Inst Own
-
Inst Trans
-
ROA
-39%
ROE
-61%
ROC
-0.46%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.01-12.75
52W High
-66.83%
52W Low
-20.4%
RSI
65.11
Rel Volume
1.79
Avg Volume
725.15K
Volume
1.3M
Perf Week
17.75%
Perf Month
23.6%
Perf Quarter
-14.96%
Perf Half Y
-37.42%
-
-
-
-
Beta
2.485
-
-
Volatility
0.14%, 0.42%
Prev Close
5.57%
Price
3.98
Change
2.84%
Company Profile
- Volume Average 725.15K
- Market Capitalization 568.97M
- Employee 186
- CEO Mr. Kabir Nath M.A., M.B.A.
- Headquarters London,GB
- IPO Date 2020-09-18
-
Website
https://compasspathways.com 
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
